Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable (TA1097)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 September 2025
Suspected Cancer: recognition and referral (update)Status:In developmentProgramme:NICE guidelineExpected publication date: 25 March 2026
Nogapendekin alfa inbakicept with intravesical BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG [ID6582]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 4 November 2026
Trastuzumab deruxtecan for previously treated unresectable or advanced HER2-positive solid tumours [ID6511]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: 13 May 2027
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer [ID6168]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer [TSID12021]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer untreated with BCG ID6454Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 20 February 2026Expected publication date: TBC
Bladder cancer: diagnosis and management (update)Status:In developmentProgramme:NICE guidelineExpected publication date: TBC
Gemcitabine intravesical delivery system for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6658]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Gemcitabine intravesical delivery system for treating recurrent high-risk papillary non-muscle-invasive bladder after BCG [ID6657]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab with BCG before surgery (neoadjuvant) for treating non-muscle-invasive bladder cancer [ID6667]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC